Bioactive properties and clinical safety of a novel milk protein peptide
| Autor: | Olof Mollstedt, Chris Rasmussen, Richard B. Kreider, Helen Chen, M Iosia, Geoffrey M. Hudson, Men-Hwei Tsai, Matthew B. Cooke |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty Short Report Medicine (miscellaneous) Antineoplastic Agents Apoptosis lcsh:TX341-641 Clinical nutrition Inhibitory Concentration 50 Double-Blind Method Internal medicine Animals Humans Medicine Epidermal growth factor receptor Caenorhabditis elegans Receptor Protein Kinase Inhibitors lcsh:RC620-627 Cancer Nutrition and Dietetics biology business.industry Kinase insert domain receptor Middle Aged Protein-Tyrosine Kinases Milk Proteins medicine.disease Vascular Endothelial Growth Factor Receptor-2 Receptor Insulin In vitro ErbB Receptors Neutrophil Lymphocyte Ratio lcsh:Nutritional diseases. Deficiency diseases Insulin receptor Endocrinology Health Insulin Sensitivity Quality of Life biology.protein Cattle Female business HT29 Cells lcsh:Nutrition. Foods and food supply Tyrosine kinase |
| Zdroj: | Nutrition Journal, Vol 10, Iss 1, p 99 (2011) Nutrition Journal |
| ISSN: | 1475-2891 |
| DOI: | 10.1186/1475-2891-10-99 |
| Popis: | Background Milk protein fractions and peptides have been shown to have bioactive properties. This preliminary study examined the potential mechanisms of action and clinical safety of novel milk protein peptide (MP). Findings A novel MP mixture inhibits the tyrosine kinase activity of epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor 2 (VEGFR2), and insulin receptor (IR) with IC50 of 9.85 μM, 7.7 μM, and 6.18 μM respectively. In vitro, this multi-kinase inhibitor causes apoptosis in HT-29 colon cancer cells, and in a C. elegans worm study, showed a weak but significant increase in lifespan. A six week double-blind, placebo-controlled study involving 73 healthy volunteers demonstrated that the MP mixture is safe to consume orally. All clinical blood markers remained within normal levels and no clinically significant side effects were reported. There was some evidence of improved insulin sensitivity, neutrophil-to-lymphocyte ratio (NLR), and quality of life assessment of role of physical function. Conclusions These data in combination with the observed in vitro anti-cancer properties warrant further clinical studies to investigate this MP mixture as a potential clinical nutrition intervention for improving the quality of life and clinical outcomes in cancer patients. Trial Registration NCT01412658 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|